3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2(3H)-benzoxazolone

Based on more than ten years of experience in organic synthesis research, international vision, advanced management concepts and awareness, LTOM is committed to providing customers at home and abroad with customized development and mass production of OLED materials and composites and innovative drug intermediates. The current annual output of various small molecule chemical composites exceeds 300 tons.